DAWN

MKT CAP:$2B

Day One Biopharmaceuticals, Inc.

Market Cap

$2B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$21.53+$12.68 (+143.28%)

Apr 22, 2026

Company Details

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type I...

CEO

Jeremy Bender

IPO Date

May 27, 2021

Website

dayonebio.com

Key Metrics TTM

Revenue

$158M

+20.6% YoY

Net Income

-$107M

EPS (Diluted)

-$1.04

Free Cash Flow

-$108M

Revenue / Share

$1.53

Gross Margin

89.1%

Operating Margin

-80.8%

Net Margin

-67.8%

FCF Margin

-68.0%

P/S

14.1x

P/E

—

Earnings Reports

Q1 2026

May 5, 2026

PENDING

FY 2025

Feb 24, 2026

$158M+20.6%EPS -$1.04

Q4 2025

Feb 24, 2026

$54M+83.9%EPS -$0.21

Q3 2025

Nov 4, 2025

$40M-57.6%EPS -$0.19

Q2 2025

Aug 5, 2025

$34M+313.9%EPS -$0.29

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	-$6.0K	-$28M
Q2 22	$0	-$133.0K	-$37M
Q3 22	$0	-$165.0K	-$40M
Q4 22	$0	-$180.0K	-$43M
Q1 23	$0	-$89.0K	-$46M
Q2 23	$0	-$92.0K	-$49M
Q3 23	$0	-$99.0K	-$51M
Q4 23	$0	-$103.0K	-$60M
Q1 24	$0	-$116.0K	-$67M
Q2 24	$8M	$7M	-$115M
Q3 24	$94M	$92M	$30M
Q4 24	$29M	$26M	-$65M
Q1 25	$31M	$28M	-$41M
Q2 25	$34M	$30M	-$35M
Q3 25	$40M	$35M	-$24M
Q4 25	$54M	$48M	-$27M

Valuation

Quarter	P/S	P/E
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	271.5x	—
Q3 24	21.8x	—
Q4 24	17.0x	—
Q1 25	13.7x	—
Q2 25	11.9x	—
Q3 25	16.6x	—
Q4 25	14.1x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$22M	-$22M
Q2 22	-$30M	-$30M
Q3 22	-$23M	-$23M
Q4 22	-$35M	-$35M
Q1 23	-$26M	-$26M
Q2 23	-$42M	-$43M
Q3 23	-$37M	-$40M
Q4 23	-$41M	-$41M
Q1 24	-$50M	-$50M
Q2 24	-$49M	-$66M
Q3 24	$51M	-$5M
Q4 24	-$30M	-$31M
Q1 25	-$59M	-$63M
Q2 25	-$25M	-$21M
Q3 25	-$6M	-$6M
Q4 25	-$14M	-$18M

Capital Expenditures

Quarter	CapEx
Q1 22	$15.0K
Q2 22	$7.0K
Q3 22	$4.0K
Q4 22	$0
Q1 23	$26.0K
Q2 23	$149.0K
Q3 23	$3M
Q4 23	$8.0K
Q1 24	$0
Q2 24	$17M
Q3 24	$56M
Q4 24	$1M
Q1 25	$4M
Q2 25	$3M
Q3 25	$0
Q4 25	$4M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 22	—	+106.3%
Q4 22	—	+94.5%
Q1 23	—	+65.3%
Q2 23	—	+34.1%
Q3 23	—	+29.6%
Q4 23	—	+39.2%
Q1 24	—	+45.6%
Q2 24	—	+149.7%
Q3 24	—	+24.7%
Q4 24	—	+58.8%
Q1 25	—	+7.6%
Q2 25	+313.9%	-44.0%
Q3 25	-57.6%	-0.1%
Q4 25	+83.9%	-14.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$6M	—
Q2 22	$6M	—
Q3 22	$9M	—
Q4 22	$7M	—
Q1 23	$9M	—
Q2 23	$9M	—
Q3 23	$10M	—
Q4 23	$11M	—
Q1 24	$13M	—
Q2 24	$13M	159.1%
Q3 24	$12M	12.3%
Q4 24	$11M	37.8%
Q1 25	$13M	41.8%
Q2 25	$11M	32.1%
Q3 25	$10M	24.0%
Q4 25	$11M	20.6%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 22	$15M	$13M
Q2 22	$23M	$14M
Q3 22	$22M	$17M
Q4 22	$26M	$17M
Q1 23	$28M	$18M
Q2 23	$32M	$17M
Q3 23	$33M	$18M
Q4 23	$37M	$22M
Q1 24	$40M	$26M
Q2 24	$92M	$30M
Q3 24	$34M	$29M
Q4 24	$62M	$30M
Q1 25	$40M	$29M
Q2 25	$36M	$29M
Q3 25	$31M	$28M
Q4 25	$41M	$34M

Revenue Segments

Quarter	Product	License
Q2 24	$8M	—
Q3 24	$20M	$74M
Q4 24	$29M	$253.0K
Q1 25	$31M	$258.0K
Q2 25	$34M	$346.0K
Q3 25	$39M	$1M
Q4 25	$53M	$884.0K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$263M	$0	$263M
Q2 22	$389M	$6M	$395M
Q3 22	$121M	$253M	$374M
Q4 22	$85M	$257M	$342M
Q1 23	$49M	$269M	$318M
Q2 23	$189M	$254M	$443M
Q3 23	$241M	$164M	$406M
Q4 23	$231M	$136M	$366M
Q1 24	$270M	$48M	$318M
Q2 24	$240M	$122M	$362M
Q3 24	$423M	$136M	$558M
Q4 24	$125M	$407M	$532M
Q1 25	$33M	$440M	$473M
Q2 25	$36M	$417M	$453M
Q3 25	$43M	$408M	$452M
Q4 25	$197M	$244M	$441M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	58M	-5.8%	—
Q2 22	61M	+4.1%	—
Q3 22	71M	+16.9%	+14.7%
Q4 22	73M	+3.4%	+18.6%
Q1 23	72M	-2.0%	+23.3%
Q2 23	75M	+4.2%	+23.4%
Q3 23	86M	+14.7%	+21.0%
Q4 23	87M	+1.5%	+18.7%
Q1 24	87M	-0.6%	+20.4%
Q2 24	87M	+0.5%	+16.2%
Q3 24	97M	+11.3%	+12.8%
Q4 24	94M	-3.4%	+7.3%
Q1 25	103M	+9.7%	+18.5%
Q2 25	103M	+0.3%	+18.3%
Q3 25	103M	+0.3%	+6.6%
Q4 25	103M	0.0%	+10.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	55
Q2 22	$0	55
Q3 22	$0	55
Q4 22	$0	121
Q1 23	$0	121
Q2 23	$0	121
Q3 23	$0	121
Q4 23	$0	155
Q1 24	$0	155
Q2 24	$52.9K	155
Q3 24	$604.9K	155
Q4 24	$161.4K	181
Q1 25	$170.0K	181
Q2 25	$187.3K	181
Q3 25	$219.9K	181
Q4 25	$269	200K

Revenue / Employee